Leukemia & Lymphoma Society

BioInvent is a research-based pharmaceutical company developing innovative antibody drugs targeting cancers with unmet clinical need.Our drug development programmes are supported by our human antibody development platform. This consists of a proprietary antibody library, n-CoDeR:registered:, and in-house technology for the rapid selection, screening and identification of antibodies with excellent affinity and selectivity for targets. BioInvent has a high level of competence in antibody drug discovery, preclinical and clinical development. The Company also has many years' experience in process development and antibody manufacturing, which we carry out at our own facilities. Alongside our in house and partnered drug-development programmes we offer antibody discovery and development services to customers. BioInvent's business model and technology platform have been validated through numerous partnerships. These include a co-development agreement with Bayer, Daiichi Sankyo, Mitsubishi Tanabe, Servier and others. BioInvent employs around 50 people and is based in Lund, Sweden. The Company listed on the NASDAQ OMX Stockholm in 2001.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Turku, Finland, focused on developing innovative treatments for medical conditions with significant unmet needs. The company's pipeline includes drug candidates targeting acute trauma, cancer growth, and inflammatory diseases. Its lead product, Traumakine, is a recombinant human interferon beta-1a currently undergoing Phase III clinical trials for the treatment of acute respiratory distress syndrome (ARDS). Another significant candidate, Clevegen, is an immunotherapy designed to inhibit tumor growth and metastasis by targeting the tumor immune suppressor molecule. Additionally, Faron is developing D-ARDS, a diagnostic tool for assessing ARDS severity and monitoring patient outcomes. Established in 2003, Faron Pharmaceuticals collaborates with the MediCity unit at Turku University Medical School to further its research and development efforts.

ImCheck Therapeutics SAS is a biopharmaceutical company based in Marseille, France, founded in 2015. The company specializes in the development of immunotherapeutics aimed at addressing severe unmet medical needs, primarily in the field of immuno-oncology. ImCheck focuses on creating immuno-modulatory antibodies that target members of the butyrophilin super-family of checkpoint molecules, specifically engaging γ9δ2 T cells. Its research and development efforts are directed toward treating various cancers, including breast, gastric, and ovarian cancers, as well as other immune-related diseases. The company's innovative approach positions it at the forefront of next-generation immunotherapy solutions for patients suffering from solid tumors.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

Dimericon Therapeutics is a biotech company that focuses on exploring crosslinked helix dimers and templates for molecule development.

Immune-Onc Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic therapies aimed at treating cancer. Immune-Onc Therapeutics focuses on the tumor microenvironment and immune suppressive pathways, utilizing advanced scientific insights to create novel immuno-oncology products. The company employs a targeted approach to develop first-in-class therapeutic antibodies that disarm immune suppression in tumors, thereby enhancing the immune response against cancer. Through its differentiated pipeline, Immune-Onc Therapeutics aims to provide new treatment options for cancer patients, addressing critical needs in the field of immunology and oncology.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Carisma Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for cancer and other serious diseases through its proprietary chimeric antigen receptor macrophage technology. The company focuses on engineering macrophages and monocytes, which are specialized white blood cells, to enhance their ability to infiltrate solid tumors and deliver potent cellular immunotherapy. By leveraging advanced cell engineering techniques, Carisma aims to provide effective treatments that enable patients with solid tumors to benefit from targeted and robust cancer therapies.

Abintus Bio, Inc. is a preclinical stage gene therapy company based in Encinitas, California, founded in 2020. The company specializes in in vivo immune cell reprogramming, aiming to develop innovative products that modulate immune cells directly within their native environment. By utilizing proprietary vectors and related technologies, Abintus Bio focuses on creating a portfolio of first-in-class product candidates designed to enhance patient outcomes by empowering the immune system to combat diseases more effectively.

Kymera Therapeutics is a biopharmaceutical company based in Watertown, Massachusetts, that specializes in the discovery and development of novel small molecule therapeutics aimed at selectively degrading disease-causing proteins. The company utilizes a proprietary platform for targeted protein degradation, leveraging the body’s natural protein recycling system. Kymera is developing several programs, including the IRAK4 program for immunology-inflammation diseases such as hidradenitis suppurativa and rheumatoid arthritis, the IRAKIMiD program to address MYD88-mutated diffuse large B cell lymphoma, and the STAT3 program targeting hematologic malignancies, solid tumors, and autoimmune diseases. Founded in 2015, Kymera Therapeutics is pioneering new approaches to treat diseases that have previously been considered untreatable, focusing on previously inaccessible therapeutic targets.

University of Arkansas for Medical Sciences is an academic health center focusing on medical education, research, and clinical programs. It offers various medical services, including specialized care in areas such as women's health, cancer treatment, orthopedics, stroke care, and trauma.

Forty Seven, Inc. is a clinical-stage immuno-oncology company based in Menlo Park, California, focused on developing innovative therapies to activate macrophages in the fight against cancer. The company's lead candidate, a monoclonal antibody targeting the CD47 receptor, aims to counteract the "don't eat me" signal that cancer cells use to evade the immune system. This antibody is currently undergoing evaluation in multiple clinical trials for various cancers, including solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma, and colorectal carcinoma. In addition to its flagship program, Forty Seven is advancing other antibodies, such as FSI-189, which binds to SIRPa, and FSI-174, an anti-cKIT antibody. The company has established collaborations with Genentech and Acerta Pharma to explore additional treatment combinations in non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. Founded in 2014, Forty Seven operates as a subsidiary of Gilead Sciences.

Ryvu is a biopharmaceutical company developing small-molecule therapies that address the clinical limitations of current treatments in oncology.

OncoPep, Inc. is a biotechnology company focused on developing targeted immunotherapeutics for cancer treatment. Founded in 2010 and based in North Andover, Massachusetts, OncoPep's primary product, PVX-410, is a multi-peptide therapeutic cancer vaccine designed to target specific antigens present on multiple myeloma cells. This vaccine aims to prevent disease progression, prolong patient survival, and enhance quality of life, particularly in cases of smoldering multiple myeloma, a precursor to the disease. The company's proprietary technology, developed under the guidance of Dr. Kenneth Anderson at the Dana Farber Cancer Institute, utilizes a unique combination of peptides to stimulate the immune system to attack cancer effectively. In addition to multiple myeloma, OncoPep's investigational peptide portfolio also targets triple-negative breast cancer and various solid tumors, including those of the breast, colon, pancreas, and prostate, helping patients leverage their immune systems in the fight against cancer.

Affimed NV is a clinical-stage biopharmaceutical company focused on developing targeted cancer immunotherapies. With nearly two decades of expertise in the innate immune system, Affimed aims to provide innovative solutions to enhance cancer treatment outcomes. The company is engaged in the discovery, pre-clinical, and clinical development of antibodies that leverage innate cell engager-based medicines, addressing the limitations of existing immuno-oncology therapies. In addition to its product development efforts, Affimed also generates revenue by offering research and development services to third parties, utilizing both its own and third-party intellectual property.

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for cancers linked to abnormal gene expression and drug resistance. The company specializes in the field of epigenetics, targeting selective regulators of epigenetic function that are vital for gene expression control. Its lead product candidates include CPI-0610, currently in Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is undergoing Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is advancing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial aimed at treating solid tumors. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Epigenetix, Inc. before rebranding in March 2008.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery, development, and commercialization of novel epigenetic medicines for cancer and other serious diseases. The company has developed Tazemetostat, an EZH2 inhibitor approved for the treatment of metastatic or locally advanced epithelioid sarcoma in the United States. Additionally, Tazemetostat is being investigated in combination therapies for various cancers, including relapsed follicular lymphoma and high-risk diffuse large B-cell lymphoma, as well as in patients with platinum-resistant solid tumors and castration-resistant prostate cancer. Epizyme also works on other product candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, along with inhibitors targeting PRMT5 and PRMT1 for different types of cancers. Established in 2007, Epizyme collaborates with several prominent organizations to advance its research and development efforts.